Wells Fargo & Company Alx Oncology Holdings Inc Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Wells Fargo & Company holds 9,324 shares of ALXO stock, worth $52,587. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,324
Previous 8,296
12.39%
Holding current value
$52,587
Previous $123,000
16.26%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding ALXO
# of Institutions
114Shares Held
38.3MCall Options Held
132KPut Options Held
19.7K-
Ven Bio Partners LLC San Francisco, CA9.7MShares$54.7 Million42.27% of portfolio
-
Redmile Group, LLC San Francisco, CA4.33MShares$24.4 Million1.9% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.22MShares$23.8 Million6.29% of portfolio
-
Cormorant Asset Management, LP Boston, MA3.14MShares$17.7 Million2.02% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.72MShares$15.3 Million0.68% of portfolio
About ALX ONCOLOGY HOLDINGS INC
- Ticker ALXO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,747,100
- Market Cap $230M
- Description
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...